Genetic Components in PMR and Nephrotic Syndrome
Yes, both polymyalgia rheumatica (PMR) and nephrotic syndrome have genetic components, though they differ substantially in their genetic architecture and clinical implications.
Polymyalgia Rheumatica (PMR)
PMR is a polygenic disease with established genetic susceptibility factors 1. The genetic contribution manifests through multiple pathways:
HLA Associations
- HLA-DRB1*04 alleles show the strongest association with PMR/GCA across multiple populations 1, 2
- HLA-DRB111, DQB107, and DRB3* alleles have been identified in familial cases 3
- The HLA association varies between isolated PMR and giant cell arteritis (GCA), and differs across ethnic populations 2
Non-HLA Genetic Factors
Recent exome sequencing has revealed important findings:
- Deleterious rare alleles in NLRP12 gene are significantly associated with PMR (P = 0.0069, OR 4.49) 4
- Multigene analysis shows increased frequency of deleterious rare alleles in autoinflammatory disorder genes (P = 0.0016, OR 3.69), establishing a link between PMR and autoinflammatory pathways 4
- TNF microsatellite polymorphisms, IL-6 promoter polymorphisms, and RANTES gene variants contribute to disease susceptibility 1, 2
Familial Aggregation
Multiple reports document familial clustering:
- First-degree relatives developing PMR/GCA within months to years of each other 5, 3
- Siblings sharing specific HLA haplotypes and developing disease nearly simultaneously 3
- This familial aggregation confirms genetic predisposition, though environmental factors also play a role 5
Clinical Implications
The genetic findings indicate PMR is multifactorial with both genetic and environmental contributions 5. However, there is currently no role for routine genetic testing in PMR diagnosis or management—the diagnosis remains clinical based on characteristic symptoms, elevated inflammatory markers, and exclusion of other conditions 6.
Nephrotic Syndrome
Nephrotic syndrome has a much more substantial and clinically actionable genetic component, particularly in specific populations:
Monogenic Forms
According to KDIGO guidelines 7:
- Monogenic variants account for 30-50% of CKD stages G3b-G5 in children
- 10-30% of adult CKD cases have monogenic causes
- Diagnostic yields range from 12-65% depending on patient selection and phenotype
Polygenic and Complex Inheritance
The genetic architecture exists on a spectrum 7:
- Common variants in HLA-DR and PLA2R1 loci confer high risk for membranous nephropathy, defying the typical common variant/small effect paradigm 7
- APOL1 risk variants in populations of African ancestry represent an intermediate pattern—common variants with relatively large effects under recessive inheritance 7
- Over 250 genetic loci have been identified through GWAS studies affecting kidney function measures 7
When to Consider Genetic Testing
Genetic testing should be considered in nephrotic syndrome when 7:
- Positive family history of kidney disease
- Early age of onset (especially pediatric cases)
- Presence of extra-renal symptoms
- Glomerular or tubulointerstitial disorders (higher diagnostic yield than diabetic kidney disease)
- Evaluation of potential kidney donors related to affected recipients
Phenotype-driven gene panels or exome/genome sequencing are more efficient than sequential single-gene testing due to genetic heterogeneity 7.
Clinical Impact
Unlike PMR, genetic diagnosis in nephrotic syndrome can directly impact management through:
- Treatment modifications based on specific genetic etiology
- Family planning decisions
- Cascade testing of family members
- Ending diagnostic odysseys 7
Key Distinctions
PMR has genetic susceptibility factors but no current clinical utility for genetic testing, while nephrotic syndrome frequently has actionable genetic causes, particularly in children and young adults, making genetic testing clinically valuable in appropriate contexts 7, 4.